Accumulating evidence has shown that aberrant YBX1 expression is closely associated with tumor progression, drug resistance, metastasis and poor prognosis in cancers (Imada et al., 2013; Davies et al., 2014; Kosnopfel et al., 2014; Wu et al., 2015). The gene discussed is YBX1; the disease is neoplasm.